Intellia Therapeutics, Inc. 0JBU.L Stock
Intellia Therapeutics, Inc. Price Chart
Intellia Therapeutics, Inc. 0JBU.L Financial and Trading Overview
Intellia Therapeutics, Inc. stock price | 24.35 USD |
Previous Close | 45.3 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 76.07 USD |
Volume | 741 USD |
Avg. Volume | 629 USD |
Market Cap | 21.7M USD |
Beta (5Y Monthly) | 1.833098 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.064 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0JBU.L Valuation Measures
Enterprise Value | 3.19B USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.40572426 |
Price/Book (mrq) | 3.358596 |
Enterprise Value/Revenue | 59.735 |
Enterprise Value/EBITDA | -7.642 |
Trading Information
Intellia Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 1.833098 |
52-Week Change | 0.89% |
S&P500 52-Week Change | 20.43% |
52 Week High | 76.07 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 40.42 USD |
200-Day Moving Average | 46.23 USD |
0JBU.L Share Statistics
Avg. Volume (3 month) | 629 USD |
Avg. Daily Volume (10-Days) | 780 USD |
Shares Outstanding | 43.42M |
Float | 83.5M |
Short Ratio | N/A |
% Held by Insiders | 5.60% |
% Held by Institutions | 87.90% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -796.40% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -20.31% |
Return on Equity (ttm) | -40.14% |
Income Statement
Revenue (ttm) | 53.48M USD |
Revenue Per Share (ttm) | 0.67 USD |
Quarterly Revenue Growth (yoy) | 12.00% |
Gross Profit (ttm) | -367858000 USD |
EBITDA | -418008000 USD |
Net Income Avi to Common (ttm) | -430440000 USD |
Diluted EPS (ttm) | -5.064 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 933.54M USD |
Total Cash Per Share (mrq) | 10.59 USD |
Total Debt (mrq) | 126.13M USD |
Total Debt/Equity (mrq) | 10.59 USD |
Current Ratio (mrq) | 9.321 |
Book Value Per Share (mrq) | 13.518 |
Cash Flow Statement
Operating Cash Flow (ttm) | -362814016 USD |
Levered Free Cash Flow (ttm) | -213832496 USD |
Profile of Intellia Therapeutics, Inc.
Country | United Kingdom |
State | MA |
City | Cambridge |
Address | 40 Erie Street |
ZIP | 02139 |
Phone | 857 285 6200 |
Website | https://www.intelliatx.com |
Industry | |
Sector(s) | |
Full Time Employees | 598 |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Q&A For Intellia Therapeutics, Inc. Stock
What is a current 0JBU.L stock price?
Intellia Therapeutics, Inc. 0JBU.L stock price today per share is 24.35 USD.
How to purchase Intellia Therapeutics, Inc. stock?
You can buy 0JBU.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Intellia Therapeutics, Inc.?
The stock symbol or ticker of Intellia Therapeutics, Inc. is 0JBU.L.
How many shares does Intellia Therapeutics, Inc. have in circulation?
The max supply of Intellia Therapeutics, Inc. shares is 477.87K.
What is Intellia Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Intellia Therapeutics, Inc. PE Ratio is now.
What was Intellia Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Intellia Therapeutics, Inc. EPS is -5.064 USD over the trailing 12 months.